Additive Effects of ns-MRA and SGLT2i: Efficacy and Safety in the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Amy Mottl, MD, MPH
Muthiah Vaduganathan, MD, MPH
Difelikefalin: Managing CKD-aP for Improved Quality of Life
Jörg Latus, MD
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Prof. Christoph Wanner
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Anuradha Lala-Trindade, MD
Brendon Neuen, MBBS, PhD
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Riccardo Maria Inciardi, MD, PhD
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Finnian R. McCausland, MD
The CONFIDENCE Trial: Data Insights
prof. Hiddo Heerspink
Albuminuria Change and Finerenone's Effect on CV Outcomes
Topline Results of the CONFIDENCE Trial
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
Jennifer B. Green, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
FCS: Enhancing the Diagnosis
Daniel Gaudet, MD, PhD
Latest Clinical Trial Outcomes and Breakthroughs for FCS
Pam R. Taub, MD, FACC, FASPC
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.